Introduction
Alzheimer's disease (AD) is the most common cause of cognitive impairment, accounting for over 60% of all dementia cases [1] . Dementia experts can diagnose "probable AD" with a sensitivity and specificity of only 71% compared with brain histopathology [2] . As many as 39% of patients diagnosed with non-AD dementia show histopathological features of AD on postmortem examination, while up to 25% of patients with a clinical diagnosis of AD have no amyloid pathology at autopsy [2] . Diagnosis of AD thus remains challenging, especially in younger patients (early-onset dementia), patients with complex clinical presentations (i.e., atypical nonamnestic clinical profiles such as predominant language, visuospatial, or behavioral symptoms), patients with mixed conditions [3] , as well as in those presenting with an unexpected rate of progression (see Supplementary Material) [4, 5] . Although diseasemodifying medications do not exist yet for AD, timely introduction of an improved diagnostic pathway has the potential to provide actual health benefits to patients presenting with cognitive decline and may also be cost-effective [6] . Uncertainty of diagnosis, especially when it lasts a long time, may have devastating effects on quality of life and health of patients with dementia [7] .
AD-specific biomarkers, such as amyloid beta (Ab), are now detectable in vivo and can be measured directly through positron emission tomography (PET) using amyloid-specific ligands [8] or indirectly by assessing Ab42 levels in cerebrospinal fluid (CSF) [9] . Amyloid imaging for detection of neuritic plaques has high sensitivity and specificity compared with histopathology as standard of truth [10] [11] [12] . It has been demonstrated that a reduced CSF level of Ab42 in patients with AD is due to Ab deposition and, thus, reflects plaque (or fibrillar Ab) load in the brain [9] . An inverse relation has been described between CSF Ab42 levels and binding of amyloid PET tracers in cortical brain regions [13] , and the high concordance between CSF Ab42 and amyloid PET imaging (see Supplementary Material and [9, 14] ) suggests that they may be used interchangeably to aid clinical diagnosis workup. Although in many countries analysis of CSF AD biomarkers has been accepted as standard practice to improve diagnostic certainty in patients with atypical neurocognitive decline [15] , the use of amyloid PET remains restricted to the research setting.
Several past and present studies investigate the cumulative utility of amyloid imaging on the routine clinical diagnostic assessment of large sets of patients evaluated for cognitive impairment in memory clinics (see Table 1 ). Population of patients and inclusion criteria of course vary, with respect to the use of appropriate use criteria (AUC) recommendations. Nevertheless, only a few studies have been implemented in natural settings, and specifically in tertiary memory clinics. Finally and above all, none of them selectively used CSF biomarker information to improve diagnostic dilemmas before PET assessment. For example, Zwan et al. [16] included patients with early-onset or mild dementia, who benefited of a lumbar puncture (LP), but CSF results were not disclosed before PET data were available and were not taken into account for the initial diagnosis, thereby altering the natural setting. In daily practice, LP cannot be performed in all patients for whom CSF analysis would otherwise be recommended because of medical reasons such as use of oral anticoagulants or spinal problems or because of patient refusal. Moreover, variability of CSF analyses is common between and within laboratories, in particular for Ab1-42 and phosphorylated tau, which may have a large impact on CSF-based AD diagnosis in clinical settings [32] . Clinicians interpret profiles of CSF biomarkers within a clinical context [33] , which, in case of limit values, or partial abnormalities associated with complex clinical situations, may prompt them to consider the CSF results as "noncontributory." In this clinical context, it is unknown whether amyloid imaging provides cumulative utility in routine clinical diagnostic assessment including collection of CSF. In the present study, we have addressed this issue with a hierarchical approach and applied it to the French clinical setting within a network of tertiary memory clinics and with respect to national recommendations [34] .
Florbetaben is a radiopharmaceutical approved in Europe and indicated, in conjunction with clinical evaluation, for PET imaging of Ab neuritic plaque density in the brains of adults with cognitive impairment who are being evaluated for AD. A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.
The present study is the first trial that explores whether florbetaben PET imaging provides added value for the assessment of complex dementia patients without interfering with the current clinical setting, including use of LP wherever possible and in line with current practice in European expert centers [15] . Amyloid PET is only introduced as a "second-line" indication for patients in whom the etiology of symptoms remained uncertain after a complete diagnostic workup and in absence of conclusive CSF results. In detail, the trial investigates whether amyloid PET imaging in patients under investigation for AD for whom LP was either contraindicated or refused, or did not provide conclusive results to the clinician, leads to changes of diagnosis and higher levels of diagnostic confidence and alterations in patient management.
Methods

Participants
Eligible patients were evaluated for AD in tertiary memory centers and had a preliminary uncertain diagnosis after a prior comprehensive workup, according to recommendations from the French Health Authority (HAS) [34] . Because of the diagnostic uncertainty, CSF examination was planned in these patients but was not obtained or not considered helpful by the expert clinician for one of the following reasons: (1) LP was refused by the patient; (2) LP was not feasible for medical reasons; or (3) results of CSF analysis were considered as noncontributory by the clinician (e.g., uninterpretable due to technical problems, values close to threshold, only one abnormal biomarker out of three, only two abnormal biomarkers out of three, or result not consistent with clinical information). All patients, who were included in the study, fulfilled at least one of the AUC as defined by Johnson et al. in 2013 [8] and were in accordance with national recommendations [34] . Full eligibility criteria are provided in the Supplementary Material. All participants or their legal representative provided written informed consent for study participation, visits, and data source verification. The study was conducted in accordance with the Declaration of Helsinki after approval of Ethics Committees.
Study design
This was a phase 4 multicenter open-label study (ClinicalTrials.gov: NCT02681172) conducted in the outpatient setting of 18 French tertiary memory clinics, without interfering with the natural clinical setting. All participating clinical sites belong to an established network of university and regional expert centers, which have the mission to contributing to diagnosis of patients with complex clinical situations and provide support for secondary-level structures, that is, private specialists and memory centers in local hospitals. The participating investigators are either neurologists or geriatricians, with a long-standing experience in dementia, sharing homogeneous practices, and with access to a technical platform, including the possibility of performing CSF analyses and functional imaging examinations. Further details of the diagnostic workup in accordance with national guidelines [34] are summarized in Supplementary Fig. 1 .
Each patient had three outpatient clinic visits: a screening/baseline visit to record information on previous workups and to establish an initial diagnosis (visit 1), a florbetaben PET scan (visit 2), and a follow-up visit at which patients were informed of the PET scan result and a final diagnosis was established (visit 3). Diagnostic certainty was assessed using a five-point Likert scale. Clinicians could report up to three possible diagnoses for each patient and indicate the probability by rank order. Level 1 was defined as the most probable of up to three potential hypotheses (levels 1-3). Management changes were defined as initiation or withdrawal of any medication, additional diagnostic tests, referral to other specialists, or providing additional explanation or advice for patients and their families. Full details are provided in the Supplementary Material.
Imaging protocol and visual assessment
Florbetaben PET images were acquired 90-110 minutes after intravenous injection of 300 MBq (620%) florbetaben according to a standardized acquisition and imageprocessing protocol [10] established during a technical visit to each center. PET image interpretation was performed locally in each center by nuclear physicians, who had undergone training for appropriate interpretation of scans. For each individual site, florbetaben scans were assessed by the associated nuclear physician. Results were interpreted as either "positive" or "negative" based on regional cortical tracer uptake assessment of the lateral temporal cortex, frontal cortex, posterior cingulate cortex/precuneus, and parietal cortex, as described previously [10] .
Statistical methods
All patients from the full analysis set were included in the per-protocol set, as no major protocol deviations were reported. To test whether potential added value of florbetaben imaging is present for different patient categories classified according to clinical status, PET categorization, or reason of eligibility, additional subgroups were analyzed (subgroup 1: patients who refused LP; subgroup 2: patients in whom LP was not possible due to medical reasons; subgroup 3: patients with noncontributory results from CSF analysis according to the clinician). These are presented in Supplementary Tables 2-6 
Results
Diagnostic workup and diagnosis before PET scan
The full study cohort included 205 patients, of whom 42.4% (n 5 87) underwent LP (Fig. 1) . Baseline characteristics of patients are shown in Table 2 . Based on the prescan diagnostic workup, the most frequent diagnosis hypothesis (probability level 1) was AD (72.2%; n 5 148); more than web 4C=FPO web 4C=FPO Fig. 1 . Patient disposition and subgroups. *All patients who received florbetaben, had a PET/computed tomography image, and in whom etiology of symptoms remained unexplained after a complete diagnostic workup. **Two subjects who refused lumbar puncture were also contraindicated for the procedure. Abbreviation: PET, positron emission tomography.
four-fifths of these cases were represented by a complex clinical situation (atypical form, early-onset AD, and rapidly progressive AD) ( Table 3) . A neurodegenerative (ND) non-AD dementia or mixed dementia was initially suspected in 15.6% (n 5 32) and 8.3% (n 5 17) of subjects, respectively. A non-ND cause of dementia was reported in 4.9% (n 5 10) of subjects. Overall, baseline confidence in the initial diagnosis was moderate (52.3%).
Scan results
In total, 64.4% of scans (132/205) were evaluated as amyloid positive on florbetaben PET, while 35.6% (73/205) were evaluated as amyloid negative. Supplementary  Fig. 3) , and in the three subsets of patients according to reason of eligibility (Supplementary Table 4 ). Demographic characteristics and global cognitive level, eligibility criteria, and prior diagnostic workup in the 12 months immediately preceding study entry were compared between patients with changed and unchanged diagnosis and for patients Tables 5 and 6 ). The between-group comparison did not show any significant differences on these variables. Frequencies of the four possible underlying etiologies for diagnosis based on probability level 1 for patients with a changed diagnosis are shown in Fig. 2 . Of PET-negative subjects, 95.1% (58/61) fell into a category other than AD after scan result disclosure. Before the scan, only 32.8% (20/61) of these subjects were categorized as other than AD. Similarly, 86.8% (66/76) of PET-positive subjects were diagnosed with AD after PET result disclosure, whereas only 63.2% (48/76) were considered to have some form of AD at initial diagnosis.
The baseline confidence was moderate (52.3%). Diagnostic confidence improved significantly after PET (Fig. 3) , with improved confidence reported for 167/205 cases (81.5%; P , .0001), and similar results found across subgroups ( Table 4 ). Most of the changes included an improvement by one category (n 5 94 subjects, Fig. 3) , and overall diagnostic confidence improved by 30.2% leading to a confidence of 82.6% after PET disclosure.
Changes in management were reported for 80.0% (164/ 205) of patients ( Supplementary Fig. 4 ). Substantial management changes (i.e., any change in initiation or withdrawal of medication, additional diagnostic tests, or referral to a new specialist) were reported in 50.7% (104/205) of patients (Table 5 ). Results were similar for different subgroups (Supplementary Table 4 ). Two exemplary clinical cases are presented in Supplementary Fig. 2 .
Increase in confidence, change in diagnosis, and change in management after PET were correlated with the initial diagnostic confidence. All three parameters were changed more often or showed a stronger increase for subjects with lower pre-PET diagnostic certainty (Supplementary Fig. 3 ).
Discussion
This is the first clinical prospective study that has sought to define the impact of amyloid PET on diagnosis and management in cases corresponding to the highest level of diagnosis uncertainty-early-onset dementia and atypical web 4C=FPO web 4C=FPO Fig. 2 . Etiology of 137 patients with a change in diagnosis after positron emission tomography (PET) scan. Etiology was defined based on level-1 hypothesis of initial diagnosis (gray) and final diagnosis (colored). The data set included 76 subjects with positive PET and 61 subjects with a negative PET; not all changes are based on a level-1 change. Abbreviations: AD, Alzheimer's disease; ND, neurodegenerative; non-AD, neurodegenerative non-Alzheimer's disease; mixed, mixed dementia. Abbreviations: AD, Alzheimer's disease; CJD, Creutzfeldt-Jakob disease.
*Clinicians could report up to three possible diagnoses for each patient and indicate the probability by rank order. Level 1 was defined as the most probable of up to three potential hypotheses. y Two patients had two level-1 diagnoses with equal probability. z Three patients had two level-1 diagnoses with equal probability (most patients had more than one potential hypothesis, illustrating the level of uncertainty and the complexity of the cases).
nonamnestic clinical profiles (e.g., predominant language, visuospatial, or behavioral symptoms, and unexpected rate of progression) [34, 35] -without interfering with the specific processes applied in the naturalistic setting of tertiary memory clinics. Because of a long-established national implementation of LP in the workup for such complex clinical situations, a hierarchical diagnostic design was adopted, with amyloid PET imaging being positioned "second line" and only considering patients that did not benefit from a recommended AD biomarker assessment using CSF.
In detail, the present study population consisted of patients eligible for CSF evaluation but in whom LP was refused by the patient or was not feasible due to medical reasons, or in whom CSF results were judged by clinicians to be noncontributory (i.e., ambiguous or inconsistent with the clinical profile). In these patients, visual interpretation of florbetaben PET led to a high percentage of clinicians (66.8%) altering their initial diagnosis. Previous studies investigating the influence of amyloid imaging on diagnostic evaluation in a more general context report change rates of diagnosis between 9.5% and 54 .6% [4,16,19,24,27,29,36] . The high proportion of diagnostic changes reported here is most likely a result of the high-level diagnostic uncertainty in this very complex population. This hypothesis is supported by the finding that changes in diagnosis were statistically more common in patients with lower pre-PET diagnostic certainty within this study cohort.
Although it is demonstrated in previous studies that Ab42 measurements in the CSF and amyloid PET are correlated and are often interchangeable for the purpose of diagnosing AD, it is not clear how different biomarkers (both CSF and PET) relate in patients with such complex presentations. For example, a recent study showed that CSF profiles in atypical AD are more heterogeneous than what is reported in typical AD subjects [37] . In the light of the already complex clinical situations of the included patients and from the clinician's point of view, ambiguous CSF profiles did not provide further insights to solve those clinical dilemmas and diagnoses were still formulated with relatively low certainty. This is in line with previous findings, showing that clinicians are influenced by CSF AD biomarkers; however, diagnosis changes are not reported for ambiguous CSF biomarker constellations [38] . The concrete impact of ambiguous CSF results on diagnosis and patient web 4C=FPO web 4C=FPO Fig. 3 . Diagnostic confidence before and after florbetaben positron emission tomography (PET) and change in diagnostic confidence (per-protocol population). management changes was not evaluated in this study, and thus, the diagnostic impact of CSF cannot be derived. Further analysis on the relationship between CSF markers, amyloid imaging, and clinical findings in such a population is important to understand the details of such complex patients.
As reported in earlier studies [16, 27] , change in diagnosis was correlated with confidence in the initial diagnosis. Change in diagnosis was particularly frequent when PET scan was negative (83.6% of cases), which is also in line with previous findings [19] . Given the high negative predictive value of amyloid imaging in histopathology studies [10] , this result is not surprising and indicates that a negative amyloid scan is generally used by dementia experts as a validated method to exclude a diagnosis of AD in most complex cases. Of the 61 PET-negative subjects with a changed diagnosis, only 3 (4.9%) were considered to be AD after florbetaben assessment, while 41 (67.2%) were categorized as AD before scan. Similarly to what has been previously acknowledged for CSF [39] , our findings suggest that clinicians do not view amyloid PET in a vacuum but instead consider its utility in combination with other clinical details and available assessments to establish decisions.
Diagnostic confidence increased for 81.5% of the subjects after PET result disclosure, and the strongest confidence increases were observed in subjects with relatively low certainty in the initial diagnosis. Most of the changes included a confidence increase by one category leading to an overall diagnostic increase of 30.2% after disclosure of PET results, which is higher than most previously reported values [4, 19, 21] . However, given the very low diagnostic confidence at baseline, the particularly distinct impact is not surprising and in general in alignment with previous studies. For example, change in diagnosis and increase in diagnostic confidence were lower in studies with higher pre-PET diagnostic confidence [4, 27] . It is thus hypothesized that amyloid PET scans have the greatest impact in situations with significant diagnostic concerns after a standard workup has been completed before PET. This is supported in at least one trial [21] . In the present study, the general confidence increase was also reflected by a reduced number of provided diagnosis hypotheses after PET disclosure.
After florbetaben PET, changes in management were reported for 80.0% of patients. Even when considering only management changes presumed to have a substantial impact on patients (i.e., new medication initiated, medication withdrawn, additional diagnostic tests, referred to another specialist), changes were still reported for 50.7% of patients. These results are in line with an earlier study that used similar criteria, with changes in management reported in 87% of patients after amyloid PET [4] . In other studies of amyloid PET, however, fewer management changes were reported (range, 37%-68%) [16, 40] . Various factors, such as differences in methodological definitions, selected variables of patient management, and diagnostic uncertainty before PET assessment, may have contributed to the differences in findings. Interestingly, changes in management were more common in patients with low pre-PET diagnostic confidence.
One concern of the study design is that patients who present medical contraindications that prevent LP, patients who refuse LP, and patients in whom an LP has been achieved might represent significantly different populations. We analyzed these subgroups and found no differences in the distribution of level-1 pretest diagnosis; the percent positive or negative scans; or percent change in diagnosis, diagnostic confidence, or management.
Although the diagnostic accuracy of amyloid PET tracers has been thoroughly assessed in several pivotal histopathology studies [10] [11] [12] , such information cannot be available in the context of clinical utility studies. Clinical follow-up of the population may provide additional and long-term insights on the impact of amyloid PET on diagnostic and patient management changes. Another limitation of the present study was the binary visual readout of amyloid PET scans. Although this approach reflects clinical routine usage, we cannot make further statements related to potentially ambiguous PET cases. Previous publications have demonstrated high concordance between visual assessment and quantification methods [41] [42] [43] , and therefore, semiquantitative approaches may provide adjunct information that might be useful, particularly, for ambiguous cases close to standardized cutoffs. Finally, factors such as degree of experience with amyloid and the physician's beliefs on the clinical value of amyloid imaging may influence interpretation of results and were not controlled for in the study.
The present study was designed with reference to a specific health care model and was restricted to an established network of tertiary memory centers. It focused on a highly selected patient population and included a hierarchical positioning of AD biomarkers, with CSF collection in first line. Several other utility studies are currently being conducted and will further contribute to our knowledge on the impact of amyloid imaging in larger clinical scenarios such as the Imaging Dementia-Evidence for Amyloid Scanning initiative which will enroll .18,000 patients, following AUC recommendations put forward by Johnson et al. [8] .
In conclusion, this naturalistic study provides evidence that visual interpretation of florbetaben PET has a strong impact on diagnostic outcome parameters and management of patients in whom uncertainty is particularly commonthat is, in early-onset, atypical, mixed, and rapidly progressing presentations-even when they firstly benefited from expert centers' assessments. Given the general diagnostic validity of amyloid PET and the previously reported high concordance rates between imaging and CSF Ab42 levels [9, 13, 36] , it is obvious that PET can efficiently substitute LP in absence of valuable CSF results. Moreover, this study shows that outcome measures of initial assessment are significantly improved in most complex cases. Most patients from this study share a very low pre-PET confidence in the initial diagnosis. There is an ethical imperative to establish an early, validated diagnosis wherever possible [44] . Moreover, it has been shown that a clear diagnosis has a positive impact on caregivers of dementia patients [21] . Providing a higher quality of diagnosis, in terms of unambiguity, may directly contribute to increase the positive impact of memory assessment services on patients' health-related quality of life [45] . From this point of view, our results highlight the immediate clinical utility of amyloid PET imaging for patients with complex dementia presentations in the context of the existing health care framework.
